279 related articles for article (PubMed ID: 36200041)
1. Emerging roles of purinergic signaling in anti-cancer therapy resistance.
Zanoni M; Pegoraro A; Adinolfi E; De Marchi E
Front Cell Dev Biol; 2022; 10():1006384. PubMed ID: 36200041
[TBL] [Abstract][Full Text] [Related]
2. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
3. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
de Andrade Mello P; Coutinho-Silva R; Savio LEB
Front Immunol; 2017; 8():1526. PubMed ID: 29184552
[TBL] [Abstract][Full Text] [Related]
4. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
5. Purinergic signaling in kidney disease.
Menzies RI; Tam FW; Unwin RJ; Bailey MA
Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
[TBL] [Abstract][Full Text] [Related]
6. Purinergic Signaling Within the Tumor Microenvironment.
Draganov D; Lee PP
Adv Exp Med Biol; 2021; 1270():73-87. PubMed ID: 33123994
[TBL] [Abstract][Full Text] [Related]
7. Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
Shafaghat Z; Ghomi AK; Khorramdelazad H; Safari E
Inflammopharmacology; 2023 Dec; 31(6):3005-3020. PubMed ID: 37805959
[TBL] [Abstract][Full Text] [Related]
8. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.
Beldi G; Enjyoji K; Wu Y; Miller L; Banz Y; Sun X; Robson SC
Front Biosci; 2008 Jan; 13():2588-603. PubMed ID: 17981736
[TBL] [Abstract][Full Text] [Related]
9. The Role of Purinergic Signaling in Heart Transplantation.
Jiang Y; Lin J; Zheng H; Zhu P
Front Immunol; 2022; 13():826943. PubMed ID: 35529844
[TBL] [Abstract][Full Text] [Related]
10. Extracellular ATP signaling and clinical relevance.
Dou L; Chen YF; Cowan PJ; Chen XP
Clin Immunol; 2018 Mar; 188():67-73. PubMed ID: 29274390
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer and Purinergic Signalling: An Overview.
Roliano GG; Azambuja JH; Brunetto VT; Butterfield HE; Kalil AN; Braganhol E
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230810
[TBL] [Abstract][Full Text] [Related]
12. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
13. [Progress on role of extracellular ATP and its metabolite adenosine in immunoregulation: Review].
Wang C; Yin Q; Su Z; Xia L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Dec; 36(12):1134-1140. PubMed ID: 33325366
[TBL] [Abstract][Full Text] [Related]
14. Emerging Roles of Purinergic Signaling in Diabetes.
Fotino C; Dal Ben D; Adinolfi E
Med Chem; 2018; 14(5):428-438. PubMed ID: 29485002
[TBL] [Abstract][Full Text] [Related]
15. Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.
Meyer AV; Klein D; de Leve S; Szymonowicz K; Stuschke M; Robson SC; Jendrossek V; Wirsdörfer F
Front Oncol; 2020; 10():554883. PubMed ID: 33194619
[TBL] [Abstract][Full Text] [Related]
16. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Stagg J; Golden E; Wennerberg E; Demaria S
Sci Immunol; 2023 Jul; 8(85):eabq3015. PubMed ID: 37418547
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and hypertension: Pivotal involvement of purinergic signaling.
Reichert KP; Castro MFV; Assmann CE; Bottari NB; Miron VV; Cardoso A; Stefanello N; Morsch VMM; Schetinger MRC
Biomed Pharmacother; 2021 May; 137():111273. PubMed ID: 33524787
[TBL] [Abstract][Full Text] [Related]
18. Purine Release, Metabolism, and Signaling in the Inflammatory Response.
Linden J; Koch-Nolte F; Dahl G
Annu Rev Immunol; 2019 Apr; 37():325-347. PubMed ID: 30676821
[TBL] [Abstract][Full Text] [Related]
19. Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance.
Aria H; Rezaei M; Nazem S; Daraei A; Nikfar G; Mansoori B; Bahmanyar M; Tavassoli A; Vakil MK; Mansoori Y
Front Immunol; 2022; 13():947885. PubMed ID: 36072596
[TBL] [Abstract][Full Text] [Related]
20. Extracellular purines, purinergic receptors and tumor growth.
Di Virgilio F; Adinolfi E
Oncogene; 2017 Jan; 36(3):293-303. PubMed ID: 27321181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
